Open AccessTwo cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab
Author(s) -
Norihiro Furutera,
Naoya Fukunaga,
Jun Okita,
Tomoko Suzuki,
Yusaku Suenaga,
Yuzo Oyama,
Koji Aoki,
Akira Fukuda,
Takeshi Nakata,
Noriko Uesugi,
Tsutomu Daa,
Satoshi Hisano,
Hirotaka Shibata
Publication year - 2020
Publication title -
cen case reports
Language(s) - English
Resource type - Journals
ISSN - 2192-4449
DOI - 10.1007/s13730-020-00511-8
Subject(s) - tocilizumab , medicine , nephrotic syndrome , renal biopsy , proteinuria , nephrology , gastroenterology , nephropathy , amyloidosis , pathology , biopsy , kidney , disease , endocrinology , diabetes mellitus
We report two cases of idiopathic multicentric Castleman disease (iMCD) with nephrotic syndrome (NS) treated with tocilizumab. Case 1 was a 58-year-old man diagnosed with iMCD prior to the onset of NS. Renal biopsy revealed membranous nephropathy, which was considered to be secondary membranous nephropathy associated with iMCD. Case 2 was a 49-year-old woman diagnosed with iMCD prior to NS. Renal biopsy revealed renal amyloidosis positive for Congo red staining and amyloid A protein immunostaining. In both the cases, the proteinuria improved after the initiation of glucocorticoid and tocilizumab therapy. Tocilizumab may be a good therapeutic choice for iMCD with NS.